Skip to content

Topics: Medicine, Pharmaceuticals

  • Cultured mini-organs reveal the weapons of aggressive bacteria

    Thanks to lab-grown miniature intestines, researchers at Uppsala University have successfully mapped how aggressive Shigella bacteria infect the human gut. The study opens the door to using cultured human mini-organs to investigate a wide range of other serious infections.

  • Trio behind Alzheimer’s drug receives Uppsala University Innovation and Entrepreneurship Award

    The drug that slows down Alzheimer’s disease is already being used by more than 20,000 patients in 10 different countries – and could soon be available in Europe too. The success story is down to the two founders of BioArctic Lars Lannfelt and Pär Gellerfors and the company’s CEO Gunilla Osswald. Their achievement is now recognised by the Uppsala University Innovation and Entrepreneurship Award.

  • Different menopausal hormone treatments pose different risks

    Researchers have analysed the effects of seven different hormone treatments for menopausal symptoms, and the risk of blood clots, stroke and heart attack. The risks differ depending on the active substance and how the medicine is taken. The study involves around one million women aged 50-58 and is the largest and most comprehensive study of currently prescribed hormonal substances in the world.

  • Genetic variation enhances cancer drug sensitivity

    By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups. This is shown in a recent study from Uppsala University, published in the journal eBiomedicine. The findings suggest a potential for more individually tailored and more effective cancer therapies.

  • Patients may become unnecessarily depressed by common heart medicine

    All patients who have had a heart attack are typically treated using beta blockers. According to a Swedish study conducted earlier this year, this drug is unlikely to be needed for those heart patients who have a normal pumping ability. Now a sub-study at Uppsala University shows that there is also a risk that these patients will become depressed by the treatment.

  • Olof Rudbeck Day with focus on AI in care and health

    What are the opportunities of using AI in healthcare? And what potential risks does it entail? These issues will be discussed during the Olof Rudbeck Day on 18 October. This year’s Rudbeck Prize winner, Ulf Gyllensten, will also give a lecture on his research into gynaecological cancer.

  • Cow slime can help disc herniation patients after surgery

    Researchers at Uppsala University have developed a gel inspired by cow slime for patients suffering from disc herniation. By adding the mucin gel immediately after surgery, it is possible to create a protective barrier around the discs to prevent the immune system from attacking their nucleus pulposus. This keeps the discs intact and reduces the risk of further damage.

  • Promising treatment for rectal cancer confirmed in major study

    A new treatment for locally advanced rectal cancer shows favourable results in that surgery can sometimes be avoided completely. It also reduces the risk of recurrence. The method has been confirmed as effective in a comprehensive study conducted at Uppsala University and published in eClinicalMedicine.

  • Lymphoma patients at high risk of infections after diagnosis

    Every year, around 100 people are affected by mantle cell lymphoma. A study at Uppsala University shows that these patients are more vulnerable to other diseases and that the risk of infection for this type of patient should therefore be carefully evaluated. The results of the study have been published in the journal Hemasphere.

  • New discovery concerning occurrence of antibiotic resistance

    A new study shows how heteroresistance, a transient resistance common in many bacteria, can act as a precursor to the development of antibiotic resistance. According to researchers at Uppsala University, this is the first time this link has been demonstrated.

  • Double risk of dementia after mouth ulcer virus

    People who have had the herpes virus at some point in their lives are twice as likely to develop dementia compared to those who have never been infected. A new study from Uppsala University confirms previous research on whether herpes can be a possible risk factor for dementia.

  • Difficult decisions led to unequal vaccination rates

    There was a significant difference in the speed with which different groups were vaccinated against COVID-19. One explanation could be that people absorb information and make decisions in different ways. A new study shows that among people with the highest cognitive ability, 80% had been vaccinated within 50 days. Among those with the lowest cognitive ability, it took 180 days to achieve the same

  • Personalised blood pressure treatment more effective

    Patients treated with blood pressure-lowering drugs can experience much greater improvements from a change of medication than from doubling the dose of their current medication. This is shown by a new study from Uppsala University, published in the Journal of the American Medical Association. In this study, 280 patients tested four different blood pressure-lowering drugs over the course of a year.

  • Oral contraceptives and hormone therapy increase the risk of stroke

    Oral contraceptives and hormone therapy at menopause increase the risk of stroke. The increased risk is greatest during the first year of treatment and then declines. The study, which is now published in Stroke, is based on data from over a quarter of a million women from the UK Biobank database.

  • More chemicals, fewer words: exposure to chemical mixtures during pregnancy alters brain development

    By linking human population studies with experiments in cell and animal models, researchers have provided evidence that complex mixtures of endocrine disrupting chemicals impact children’s brain development and language acquisition. With their novel approach, the scientists show that up to 54 per cent of pregnant women were exposed to experimentally defined levels of concern.

  • Promising molecule for treatment of COVID-19

    Uppsala researchers have succeeded in designing a molecule that inhibits the replication of coronaviruses and that has great potential for development into a drug suitable for treating COVID-19. The molecule is effective against both the new variant and previously identified coronaviruses. The article has been published in the Journal of the American Chemical Society.

  • Hunt for the protein TGM1 led to disease discovery

    Searching for the protein TGM1 among patients with autoimmune skin diseases, researchers have identified a separate disease that can be linked to autoimmunity against TGM1. This backward method demonstrates a new way of identifying autoantigens as markers for serious diseases. By letting autoantigens point to the disease, diagnosis and treatment can be facilitated, shows study published in PNAS.

  • Expectations and dopamine can affect outcome of SSRI treatment

    Levels of dopamine and placebo effect can determine whether social anxieties improve when treated with SSRIs. The effect was four times higher for patients with high expectations compared with low expectations, even though the groups received the same medical treatment. Although SSRIs influence levels of serotonin in the brain, the effects on dopamine had the greatest impact for improvement.

  • T-cell tests unreliable in establishing previous COVID-19

    Can T-cell tests be used to determine whether people have had COVID-19? Scientists at Uppsala University and Karolinska Institutet have jointly analysed this issue under the aegis of the COMMUNITY study at Danderyd Hospital. Their study is published in the scientific journal PLOS ONE.

  • New method used to study how cancer cells are organised

    Changes in individual cancer cells over time may explain why brain tumours develop so differently, and why some cancer cells are resistant to certain treatments. To track the development of cancer cells, researchers at Uppsala University have devised a new method that, in the long term, may make it easier to develop new, effective drug combinations.

Show more